OncoMatch/Clinical Trials/NCT06313957
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Is NCT06313957 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies LUCAR-20SP cells for relapsed b-cell non-hodgkin lymphoma.
Treatment: LUCAR-20SP cells — This is a prospective, single-arm, open-label, exploratory clinical study of LUCAR-20SP in adult subjects with relapsed/refractory B-cell non-Hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 positive
CD20 positive
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: allogeneic cell and gene therapy (CAR-T)
Exception: subjects with evidence that previous allogeneic cell and gene therapy products (such as CAR-positive T cells and CAR transgenes) in the subject have been below the lower limit of detection
Previous treatment with allogeneic cell and gene therapy (such as CAR-T); Except subjects with evidence that previous allogeneic cell and gene therapy products (such as CAR-positive T cells and CAR transgenes) in the subject have been below the lower limit of detection
Cannot have received: allogeneic hematopoietic stem cell transplantation
Previously received allogeneic hematopoietic stem cell transplantation
Cannot have received: gene therapy
Previously received gene therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify